Starpharma EBITDA
Was ist das EBITDA von Starpharma?
EBITDA von Starpharma Holdings Limited ist -AUD$15.80
Was ist die Definition von EBITDA?
Das EBITDA ist das Ergebnis eines Unternehmens vor Zinsen, Steuern, Abschreibungen und Amortisationen und ist eine Buchhaltungsgröße, die anhand des Nettoergebnisses eines Unternehmens berechnet wird, bevor Zinsaufwendungen, Steuern, Abschreibungen und Amortisationen abgezogen werden, um die derzeitige operative Ertragskraft eines Unternehmens zu ermitteln.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Starpharma
Was macht Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Unternehmen mit ebitda ähnlich Starpharma
- Red White & Bloom Brands hat EBITDA von -CAD$15.84
- Just Kitchen hat EBITDA von -CAD$15.82
- Remark hat EBITDA von -$15.82
- Novo Resources hat EBITDA von -$15.81
- Big 5 Sporting Goods Corp hat EBITDA von -$15.81
- Star Properties (Cayman Islands) hat EBITDA von -HKD$15.80
- Starpharma hat EBITDA von -AUD$15.80
- Greenlane Inc hat EBITDA von -$15.79
- Nicox S.A hat EBITDA von -€15.78
- Nicox SA hat EBITDA von -€15.78
- Kalium Lakes hat EBITDA von -AUD$15.77
- RTW Retailwinds hat EBITDA von -$15.76
- 17033 hat EBITDA von -$15.76